Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report.

Qian HZ, Mitchell VJ, Bebawy S, Cassell H, Perez G, McGowan CC, Sterling TR, Vermund SH, D'Aquila R, Hulgan T.

BMC Infect Dis. 2014 Sep 18;14:508. doi: 10.1186/1471-2334-14-508.

2.

HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077.

Kantor R, Bettendorf D, Bosch RJ, Mann M, Katzenstein D, Cu-Uvin S, D'Aquila R, Frenkel L, Fiscus S, Coombs R; ACTG A5077 Study Team.

PLoS One. 2014 Apr 3;9(4):e93537. doi: 10.1371/journal.pone.0093537. eCollection 2014.

3.

The safe patient flow initiative: a collaborative quality improvement journey at Yale-New Haven Hospital.

Jweinat J, Damore P, Morris V, D'Aquila R, Bacon S, Balcezak TJ.

Jt Comm J Qual Patient Saf. 2013 Oct;39(10):447-59.

PMID:
24195198
4.

Yale-New Haven hospital's planning and execution of a complex hospital acquisition.

D'Aquila R, Aseltyne WJ, Lopman A, Jweinat J, Ciaccio T, Comerford MJ.

Am J Med. 2013 Aug;126(8):744-752.e12. doi: 10.1016/j.amjmed.2013.04.006. No abstract available.

PMID:
23885676
5.

Persistent genital tract HIV-1 RNA shedding after change in treatment regimens in antiretroviral-experienced women with detectable plasma viral load.

Venkatesh KK, DeLong AK, Kantor R, Chapman S, Ingersoll J, Kurpewski J, De Pasquale MP, D'Aquila R, Caliendo AM, Cu-Uvin S.

J Womens Health (Larchmt). 2013 Apr;22(4):330-8. doi: 10.1089/jwh.2012.3849. Epub 2013 Mar 26.

6.

No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.

Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, Read S, Kallungal B, Chang M, Goecker EA, Wiegand A, Kearney M, Jacobson JM, D'Aquila R, Lederman MM, Mellors JW, Eron JJ; AIDS Clinical Trials Group (ACTG) A5244 Team.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):229-35. doi: 10.1097/QAI.0b013e31823fd1f2.

7.

Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load.

Cu-Uvin S, DeLong AK, Venkatesh KK, Hogan JW, Ingersoll J, Kurpewski J, De Pasquale MP, D'Aquila R, Caliendo AM.

AIDS. 2010 Oct 23;24(16):2489-97. doi: 10.1097/QAD.0b013e32833e5043.

PMID:
20736815
8.

Effect of persistent moderate viremia on disease progression during HIV therapy.

Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D'Aquila R, Mangialardi WJ, Fusco GP; Collaborations in HIV Outcomes Research/United States Project.

J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1147-54.

PMID:
15319674
9.

Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.

Foli A, Maserati R, Barasolo G, Castelli F, Tomasoni L, Migliorino M, Maggiolo F, Pan A, Paolucci S, Scudeller L, Tinelli C, D'Aquila R, Lisziewicz J, Lori F.

Antivir Ther. 2004 Feb;9(1):123-32.

PMID:
15040544
10.

HIV-1 drug resistance assays in clinical management.

Martinez-Picado J, D'Aquila R.

AIDS Clin Care. 1998 Nov;10(11):81-5, 87-8.

PMID:
11365861
11.

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C.

J Virol. 2001 Jun;75(11):4999-5008.

12.

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.

Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S.

AIDS. 2000 Dec 22;14(18):2857-67.

PMID:
11153667
13.

The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.

DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J.

Antivir Ther. 2000 Mar;5(1):41-8.

PMID:
10846592
14.

Exploring the benefits and limits of highly active antiretroviral therapy.

D'Aquila R, Walker B.

JAMA. 1999 Nov 3;282(17):1668-9. No abstract available.

PMID:
10553795
15.

Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy.

Mayer KH, Boswell S, Goldstein R, Lo W, Xu C, Tucker L, DePasquale MP, D'Aquila R, Anderson DJ.

Clin Infect Dis. 1999 Jun;28(6):1252-9.

16.

Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group.

Demeter LM, D'Aquila R, Weislow O, Lorenzo E, Erice A, Fitzgibbon J, Shafer R, Richman D, Howard TM, Zhao Y, Fisher E, Huang D, Mayers D, Sylvester S, Arens M, Sannerud K, Rasheed S, Johnson V, Kuritzkes D, Reichelderfer P, Japour A.

J Virol Methods. 1998 Nov;75(1):93-104.

PMID:
9820578
17.

An emergency services nurse liaison program.

D'Aquila R.

J Emerg Nurs. 1995 Oct;21(5):445-6. No abstract available.

PMID:
7500576
18.

Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee.

Hammer S, Crumpacker C, D'Aquila R, Jackson B, Lathey J, Livnat D, Reichelderfer P.

J Clin Microbiol. 1993 Oct;31(10):2557-64. Review. No abstract available.

19.

Focus on innovation: profiles in creativity.

D'Aquila R.

Healthc Forum J. 1988 Nov-Dec;31(6):12-6. No abstract available.

PMID:
10290116
20.

Prevalence of HTLV-III infection among New Haven, Connecticut, parenteral drug abusers in 1982-1983.

D'Aquila R, Williams AB, Kleber HD, Williams AE.

N Engl J Med. 1986 Jan 9;314(2):117-8. No abstract available.

PMID:
3941684
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk